BNTX Form 144 Filed for 185,001 ADSs via Berenberg; Approx sale 08/15/2025

Rhea-AI Filing Summary

Form 144 filed for BioNTech SE (BNTX) reporting a proposed sale of 185,001 American Depositary Shares (ADS) representing ordinary shares. The broker listed is Berenberg Capital Markets LLC with an approximate sale date of 08/15/2025 on Nasdaq Global Select. The aggregate market value of the proposed sale is reported as $20,849,612.70 and the number of shares outstanding is listed as 240,398,724. The securities were acquired on 11/21/2022 through a stock option exercise from BioNTech SE. The filer reports no securities sold in the past three months and includes the standard certification that the seller is not aware of undisclosed material adverse information.

Positive

• Regulatory compliance: The filer provided required Form 144 details including broker, share count, and aggregate market value.
• Transparency on acquisition: The securities were identified as acquired by stock option exercise on 11/21/2022, clarifying origin of the shares.

Negative

• Insider sale proposed: The notice indicates an insider intends to sell 185,001 ADSs, which may increase share supply.
• Limited disclosure on intentions: The filing does not indicate whether the sale is under a 10b5-1 trading plan or provide pricing details beyond aggregate market value.

Insights

Financial Analyst

TL;DR Insider-originated ADS sale notice for 185,001 shares valued at about $20.85M; routine regulatory disclosure.

The Form 144 documents a proposed sale of 185,001 BioNTech ADSs acquired by stock option exercise on 11/21/2022. The notice names Berenberg Capital Markets as the broker and targets an approximate sale date of 08/15/2025 on Nasdaq Global Select. No sales in the prior three months are reported. As a market professional, I view this as a standard insider sale filing that provides transparency on potential share supply entering the market. The filing does not include pricing details beyond aggregate market value nor any explanation of intent or trading plan.

Corporate Governance Expert

TL;DR Form 144 reflects required compliance; signals an insider disposition but contains no evidence of undisclosed material information.

The filer declares the securities were acquired via stock option exercise from BioNTech SE and affirms no known undisclosed material adverse information. The filing meets procedural requirements by identifying the broker, share count, aggregate value, and proposed sale date. It does not state whether the sale is part of a Rule 10b5-1 plan or provide additional governance context. From a governance standpoint, the filing is a routine disclosure enabling market participants to monitor insider activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	Berenberg Capital Markets LLC 1251 Avenue of the Americas 53rd Floor New York NY 10020	185001	20849612.70	240398724	08/15/2025	Nasdaq Global Select

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares, no par value per share	11/21/2022	Stock Option Exercise	BioNTech SE			185001	11/21/2022	Stock Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for BioNTech (BNTX) report?

The form reports a proposed sale of 185,001 American Depositary Shares with an aggregate market value of $20,849,612.70 through Berenberg Capital Markets LLC with an approximate sale date of 08/15/2025.

When and how were the shares being sold by the filer acquired?

The shares were acquired on 11/21/2022 via a stock option exercise from BioNTech SE.

Does the Form 144 show any sales of BioNTech ADSs in the past three months?

No. The filing explicitly states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale of BNTX ADSs?

The broker listed is Berenberg Capital Markets LLC, located at 1251 Avenue of the Americas, New York.

What exchange is the proposed BioNTech sale expected to occur on?

The proposed sale is expected to occur on Nasdaq Global Select.